Free tool
FAERS Monitor: Hyrimoz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761071 or its brand name (Hyrimoz, Adalimumab-Adaz). Reports on generic versions are filed under their own applications.
Reports
55,076
Serious
50,853
92% of reports
Hospitalization
19,018
Death reported
8,503
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11,624
- off label use9,662
- rheumatoid arthritis6,561
- pain6,472
- fatigue6,470
- arthralgia6,308
- rash5,346
- condition aggravated5,087
- diarrhoea4,907
- drug intolerance4,718
- nausea4,651
- joint swelling4,643
- headache4,639
- systemic lupus erythematosus4,632
- psoriatic arthropathy4,430
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 25 |
| 2006 | 10 |
| 2007 | 44 |
| 2008 | 136 |
| 2009 | 138 |
| 2010 | 257 |
| 2011 | 208 |
| 2012 | 256 |
| 2013 | 295 |
| 2014 | 277 |
| 2015 | 318 |
| 2016 | 505 |
| 2017 | 727 |
| 2018 | 1,255 |
| 2019 | 2,236 |
| 2020 | 3,159 |
| 2021 | 3,641 |
| 2022 | 5,374 |
| 2023 | 8,070 |
| 2024 | 10,487 |
| 2025 | 10,501 |
| 2026 | 7,149 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,999,083 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic lupus erythematosusSignal | 4,632 | 57.2 | 55.5 | 222,587 |
| psoriatic arthropathySignal | 4,430 | 46.7 | 45.3 | 176,652 |
| rheumatoid arthritisSignal | 6,561 | 23.4 | 22.8 | 133,017 |
| drug intoleranceSignal | 4,718 | 19.6 | 19.0 | 79,367 |
| joint swellingSignal | 4,643 | 15.2 | 14.8 | 59,715 |
| condition aggravatedSignal | 5,087 | 6.5 | 6.3 | 23,521 |
| arthralgiaSignal | 6,308 | 5.9 | 5.7 | 25,586 |
| rashSignal | 5,346 | 4.7 | 4.6 | 15,853 |
| off label useSignal | 9,662 | 4.2 | 4.2 | 24,774 |
| painSignal | 6,472 | 4.1 | 4.0 | 15,184 |
| drug ineffectiveSignal | 11,624 | 3.4 | 3.3 | 20,701 |
| fatigueSignal | 6,470 | 3.2 | 3.1 | 10,026 |
| diarrhoeaSignal | 4,907 | 2.9 | 2.8 | 6,330 |
| headacheSignal | 4,639 | 2.8 | 2.8 | 5,653 |
| nauseaSignal | 4,651 | 2.3 | 2.2 | 3,341 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.